Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer.
The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a
never-smoker (less than 100 cigarettes lifetime) the cancer can be any type of
adenocarcinoma.